联合治疗干预与树突状细胞疗法在HIV感染者中的病毒学与免疫学结局
干预后分析性治疗中断期间,除1名参与者至84周才反弹及2名接受全部联合疗法者病毒载量维持在1000拷贝/mL以下外,所有合格参与者均在14周内反弹;这些治疗后控制者均接受含烟酰胺方案并显示免疫细胞表观遗传年龄逆转。
要点
- 多种抗储存库干预在HIV感染者中显示安全性。
- 含烟酰胺方案者中观察到治疗后病毒控制及表观遗传年龄逆转。
- 支持继续研究单药及联合干预以实现治疗后HIV控制。
核心结论
- 概念验证试验表明多种不同抗储存库活性干预在HIV感染者中是安全的。
- 支持继续研究单药和联合干预以实现治疗后HIV控制。
研究设计与样本
- 治疗包括标准ART单独或联合ART强化、金诺芬、烟酰胺及个体化树突状细胞疗法。
主要发现
- 分析性治疗中断后,所有合格参与者均在14周内反弹,除1名在84周检测到反弹。
- 2名接受全部联合疗法者病毒载量在整个研究期间维持在1000拷贝/mL以下。
- 这些治疗后控制者均接受含烟酰胺方案并显示免疫细胞表观遗传年龄逆转。
临床怎么用
- 联合抗储存库干预在HIV感染者中安全性良好,但病毒反弹普遍。
- 含烟酰胺方案可能与部分患者治疗后病毒控制及表观遗传年龄逆转相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Except for hematopoietic cell transplantation, therapeutic-driven HIV-1 curative approaches have been unsuccessful. Here, we describe a 2-step randomized clinical trial designed to evaluate the safety and impact of individual and combinatorial therapeutic strategies on changes in peripheral and gut mucosal HIV reservoirs, immune activation and function in people with HIV with chronic disease and high CD4 T-cell nadirs. METHODS: Thirty participants were enrolled and randomized equally into 6 study arms based on treatments with either standard antiretroviral therapy (ART) alone or a combination of candidate anti-HIV reservoir strategies that included ART intensification, auranofin (an apoptotic-inducer antirheumatic drug), nicotinamide (vitamin B3), and a personalized dendritic cell therapy. RESULTS: After an analytical treatment interruption post intervention, all eligible participants rebounded within 14 weeks, except for 1 participant with rebound detected at 84 weeks and 2 participants receiving all combined therapies maintained viral loads below 1000 copies/mL through the study period. These posttreatment controllers all received nicotinamide containing regimens and exhibited immune cellular epigenetic age reversal. CONCLUSIONS: This proof-of-concept clinical trial demonstrates the safety of multiple interventions with distinct antireservoir activities in people with HIV and argues for continued investigation of both single and combinatorial interventions towards posttherapy HIV control.
引用
- Ndhlovu LC, Giron LB, Galinskas J, et al. Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV. J Infect Dis. 2025. PMID: 40810569. doi:10.1093/infdis/jiaf430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。